About VELSERA | DxMultiomics

VELSERA

Velsera’s mission is to be the discovery, evidence generation, and clinical delivery platform for precision medicine. We help doctors and drug hunters make better decisions about providing the right therapy to the right patients at the right time. Velsera was founded in 2023 as a result of the merger of Seven Bridges, PierianDx and UgenTec, and operates in the US, Europe and Asia.

News Releases

Velsera and Flywheel Team up to Support Multimodal Imaging Genomics Research

_↗ businesswire.com

Apr 4, 2024

Velsera and Solaris Health Partner to Expand Access to Genetic Testing that Helps Urology Patients Understand Cancer Risks

_↗ businesswire.com

Nov 3, 2023

Velsera Makes NVIDIA Parabricks Tools Available for Global Researchers on the Seven Bridges Platform

_↗ businesswire.com

Nov 2, 2023

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.